Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (251-260 of 868) with videos related to

Pageof 87
Sort By:
Blood Cancer Journal|January 14, 2021
Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13Yan Song, Ting Du, Arghya Ray, et al.
British Journal of Haematology|April 27, 2012
A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myelomaJooeun Bae, Weihua Song, Robert Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2012
Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disordersJooeun Bae, Robert Smith, John Daley, et al.
British Journal of Haematology|March 25, 2010
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine modelAjita V Singh, Michael A Palladino, George Kenneth Lloyd, et al.
Antioxidants & Redox Signaling|February 17, 2024
DAMPening Tumor Immune Escape: The Role of Endoplasmic Reticulum Chaperones in Immunogenic ChemotherapySelma Cifric, Marcello Turi, Pietro Folino, et al.
British Journal of Haematology|January 12, 2011
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancersPaul G Richardson, Constantine S Mitsiades, Jacob P Laubach, et al.
Journal of Leukemia (Los Angeles, Calif.)|September 27, 2016
Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3<sup>+</sup>CD8<sup>+</sup> T cells against Various Solid TumorsJooeun Bae, Derin B Keskin, Kristen Cowens, et al.
Expert Opinion on Emerging Drugs|March 16, 2007
Emerging drugs in multiple myelomaIrene M Ghobrial, Xavier Leleu, Evdoxia Hatjiharissi, et al.
Annals of Hematology|January 24, 2018
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myelomaIris Breitkreutz, Klaus Podar, Vianihuini Figueroa-Vazquez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 8, 2013
Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cellsJooeun Bae, Aditya Munshi, Cheng Li, et al.
Pageof 87

Showing results (251-260 of 868) with videos related to

Sort By:
Pageof 87
Blood Cancer Journal|January 14, 2021
Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13Yan Song, Ting Du, Arghya Ray, et al.
British Journal of Haematology|April 27, 2012
A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myelomaJooeun Bae, Weihua Song, Robert Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2012
Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disordersJooeun Bae, Robert Smith, John Daley, et al.
British Journal of Haematology|March 25, 2010
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine modelAjita V Singh, Michael A Palladino, George Kenneth Lloyd, et al.
Antioxidants & Redox Signaling|February 17, 2024
DAMPening Tumor Immune Escape: The Role of Endoplasmic Reticulum Chaperones in Immunogenic ChemotherapySelma Cifric, Marcello Turi, Pietro Folino, et al.
British Journal of Haematology|January 12, 2011
Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancersPaul G Richardson, Constantine S Mitsiades, Jacob P Laubach, et al.
Journal of Leukemia (Los Angeles, Calif.)|September 27, 2016
Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3<sup>+</sup>CD8<sup>+</sup> T cells against Various Solid TumorsJooeun Bae, Derin B Keskin, Kristen Cowens, et al.
Expert Opinion on Emerging Drugs|March 16, 2007
Emerging drugs in multiple myelomaIrene M Ghobrial, Xavier Leleu, Evdoxia Hatjiharissi, et al.
Annals of Hematology|January 24, 2018
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myelomaIris Breitkreutz, Klaus Podar, Vianihuini Figueroa-Vazquez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 8, 2013
Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cellsJooeun Bae, Aditya Munshi, Cheng Li, et al.
Pageof 87